IMA901

· Immatics Biotechnologies GmbH

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMA901, covering 2012-07-10 to 2017-10-12. Get the full timeline:

Most recent: Clinical Trial Update: IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma [Phase 3]